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This paper is submitted to satisfy the course requirement for Food and Drug Law.
1Abstract: In the 1980’s, animal rights activists successfully motivated the cosmetic industry
to begin researching alternatives to animal tests. The European Union has taken action to
stimulate development and validation of alternatives to animal testing through the Sixth
and Seventh Amendments to the Cosmetics Directive. In this paper, I will brieﬂy describe
the history of the search for alternatives to animal testing for cosmetics. I will then discuss
the progress that has been made toward developing and validating replacement alternatives
in the eleven toxicological safety testing areas; alternatives are needed in all eleven areas in
order for animal tests to be totally replaced.
Introduction
For many years, European and American consumers have expressed moral concerns over animal testing of
cosmetics.1 The political momentum against animal testing gained publicity and visibility in May 1980
when 300 people, some dressed in bunny costumes, demonstrated outside Revlon’s New York oﬃces.2 In
response to continued protests and political pressure, Revlon gave a $250,000 per year grant to Rockefeller
University to research alternatives to animal testing.3 The protestors then moved onto Avon and those
protests resulted in the creation of the Center for Alternatives to Animal Testing (CAAT) at Johns Hopkins
University.4 Many other cosmetic companies also responded to consumer concerns and protests by investing
1An Overview of Animal Testing Issues, The Humane Society of the United States, at 8, available at
http://www.hsus.org/web-ﬁles/PDF/ARI/ARIS An Overview Of Animal Testing Issues.pdf. (“The use of animals to
test drugs and other therapeutic agents has the support of a majority of the American public, but there is much less support for
the animal testing of products that are deemed less essential, such as cosmetic or household cleaning products. For example,
60 percent of a sample of 1,000 American adults opposed the use of animals in cosmetics testing, compared to 43 percent and
20 percent opposing animal testing of over-the-counter medicines and prescription drugs respectively (Ward, 1990). About 90
percent of the sample said they would purchase cosmetics that had not been tested on animals.”); EBRA Bulletin, European
Biomedical Research Association, Jan. 1996, available at, http://www.ebra.org/bulletin/jan04 96.html#1 (Animal rights and
animal welfare groups in the UK have advocated for a ban on the use of animals in the testing of cosmetics and cosmetic
ingredients since 1987 and the movement spread throughout Europe in 1990.).




2signiﬁcant funds into researching alternatives to animal testing.5
In 1993, the European Parliament took legislative action to aide and encourage the search for alternatives to
animal testing for cosmetics by adopting the Sixth Amendment to the Cosmetics Directive (the Cosmetics
Directive was adopted in 1976 to regulate the manufacture and sale of cosmetic products in the European
Union).6 The Sixth Amendment banned the marketing of cosmetics containing ingredients that had been
tested on animals starting January 1, 1998.7 To facilitate the development and validation of alternatives,
the European Union created the European Centre for the Validation of Alternative Methods (ECVAM).8
ECVAM accepted a tremendous task under the Sixth Amendment because the 1998 marketing ban would
be postponed if satisfactory alternatives to animal tests had not been validated by the beginning of 1997.9
The United States followed Europe in 1997 by creating the Interagency Coordinating Committee on the
Validation of Alternative Methods (ICCVAM) and its supporting center the National Toxicology Program
Interagency Center for the Evaluation of Alternative Toxicological Methods (NICEATM) to research and
validate alternatives to animal testing.10
Despite these eﬀorts, the European Parliament was not satisﬁed that alternatives were being developed fast
enough.11 Therefore, in 2003, the European Parliament adopted the Seventh Amendment to the European
5Id.; Carmen Fleetwood, In Vitro Testing is Coming to Aid, If Not Yet Succeed, the Guinea Pig, Wall Street Journal, Sept.
19, 2004, at B.2F (For example, Proctor and Gamble has invested more than $170 million on alternatives to animal testing over
the past two decades and continues to spend $10-13 million per year on alternatives.).
6Azalea P. Rosholt, The Seventh Amendment Directive – An unnecessary measure to a necessary end – Possible legal challenges to directive 2003/15/EC of the European Parliament and of the council amending council directive 76/768/EEC under European Union law,
60 Food Drug L.J. 421, 424-25 (2005); EBRA Bulletin, supra note 1.
7Id.
8Alison Abbott, More than a Cosmetic Change, Nature, Nov, 10, 2005, at 144.
9EBRA Bulletin, supra note 1 (quoting the speciﬁc wording of the Sixth Amendment to the Cosmetics Directive: “If there
has been insuﬃcient progress in developing satisfactory methods to replace animal testing, and in particular in those cases where
alternative methods of testing, despite all reasonable endeavors, have not been scientiﬁcally validated as oﬀering an equivalent
level of protection, for the consumer, taking into account [Organisation for Economic Co-operation and Development] OECD
toxicity guidelines, the Commission shall, by 1st January 1997, submit draft measures to postpone the date of implementation
of this provision, for a suﬃcient period, and in any case for no less than two years...”).
10Overview, ICCVAM, available at http://iccvam.niehs.nih.gov/about/overview.htm; Animal Testing, U.S.
Food and Drug Administration Center for Food Safety and Applied Nutrition, June 9, 2005, available at,
http://www.cfsan.fda.gov/∼dms/cos-205.html.
11Rosholt, supra note 6, at 429 (stating “the Seventh Amendment attempts to legislate an accelerated development of
3Union Cosmetics Directive.12 The Seventh Amendment phases in a ban on the sale of cosmetic products
tested on animals and a ban on the sale of cosmetic products containing ingredients tested on animals.13
Although the Seventh Amendment has been criticized for creating unreasonable deadlines14 and for being
unnecessary,15 it has provided a catalyst for the development and validation of alternatives to animal testing
for cosmetics.16 In this paper, I will discuss the progress that has been made toward developing and validating
alternatives to animal testing.
Legal Rules for Cosmetics Safety Assessment
Consumers in the United States and Europe have come to expect the cosmetic products they use on a
daily basis to be safe.17 Despite consumer beliefs, American laws do not inspire much conﬁdence regarding
cosmetic product safety because the Food Drug and Cosmetic Act of 1938 does not require that cosmetic
manufacturers or marketers test their products for safety.18 However, the FDA does strongly urge cosmetic
alternative testing methods for the cosmetic industry”).
12Directive 2003/15/EC of the European Parliament and of the Council of 27 February 2003: Amending Council Directive 76/768/EEC on the approximation of the laws of the Member States relating to cosmetic products,
66 Oﬃcial Journal of the European Union 26 (2003), available at http://europa.eu.int/eur-
lex/pri/en/oj/dat/2003/l 066/l 06620030311en00260035.pdf; See also The European Cosmetic Directive 76/768/EEC – 7th
Amendment, available at http://www.a-t-c.org.uk/pages/index.cfm?FuseAction=ShowPage&sec=6&page=191.
13New methods replace animal testing for cosmetics, European Innovation, March, 2005,
available at http://aoi.cordis.lu/article.cfm?article=1502. (Speciﬁcally, the Directive provides for a ban on animal test-
ing of ﬁnished products (applicable from September 11, 2004), and a complete ban on animal testing of cosmetic ingredients
as soon as alternative methods are validated and adopted by EU legislation. The ﬁnal deadline of March 11, 2009 applies even
if alternative tests are not available yet. A marketing ban on animal-tested products also applies, from September 11, 2004 or
as soon as alternative methods are validated and adopted and again by March 11, 2009 at the latest, with the exception of
three study areas where development of alternatives will unavoidably take longer – alternative tests for repeated dose toxicity,
reproductive toxicity and toxicokinetics need not be introduced until March 11, 2013 (and perhaps later if technical problems
arise).)
14Rosholt, supra note 6, at 429; Geoﬀ Meade, Animal Tests Ban Deadline ‘Unrealistic’, The Press Association, Sept. 21,
2004 (“experts say the timetable is unrealistic and that it is not feasible to replace animal testing with other techniques within
10 years”).
15Rosholt, supra note 6, at 446 (“The Experimental Animals Protection Directive includes a recommendation to encourage the
development of validated reduction and reﬁnement alternatives across the board for all industries in addition to full replacement
alternatives...”, thus making the Seventh Amendment redundant legislation).
16See Abbott, supra note 8, at 144-46.
17Rosholt, supra note 6, at 421 (“No one expects to be blinded or disﬁgured by a cosmetic product, even if the product is
misused”).
18U.S. Food and Drug Administration Center for Food Safety and Applied Nutrition, Cosmetic Handbook
4manufacturers to conduct whatever tests are appropriate to substantiate the safety of their cosmetics and
if the safety of a cosmetic is not adequately substantiated, then the product may be considered misbranded
unless the label states: “Warning – The safety of this product has not been determined.”19 Although
American cosmetics safety laws are weak, this labeling requirement “is likely to persuade manufacturers to
conduct [safety] testing to avoid such labelling [sic]” and the industry has adopted a self-regulation program,
which reviews the safety of cosmetic ingredients.20
Europeans, on the other hand, have legal authority to expect cosmetic products to be safe because Article
2 of the European Union Cosmetics Directive declares: “A cosmetic product put on the market within the
Community must not cause damage to human health when applied under normal or reasonably foreseeable
conditions of use...”21 Moreover, Article 7a. 1(d) states that when assessing the safety of the cosmetic
product, the manufacturer shall consider the general toxicological proﬁle of the ingredients, their chemical
structure and their level of exposure.22
Europe has identiﬁed eleven toxicological testing areas that a cosmetic must pass to be considered safe.23
Thus, to comply with European safety laws and the Seventh Amendment, alternatives to animal testing must
be validated in the following areas: 1) Acute toxicity; 2) Skin Irritation and corrosion; 3) Eye irritation; 4)
skin sensitization; 5) Skin absorption and penetration; 6) Subacute and subchronic toxicity; 7) Genotoxicity
and mutagenicity; 8) UV-induced toxic eﬀects; 9) Toxicokinetics and metabolism; 10) Carcinogenicity; and
(1992), available at, http://www.cfsan.fda.gov/∼dms/cos-hdb1.html.; But cf. Simon Pitman,
FDA launches electronic registration system for cosmetic formulations, Decision News Media, Dec. 2, 2005, available at,
http://www.cosmeticsdesign.com/news/ng.asp?id=64303-fda-vcrp-regulation (discussing the FDA’s recently launched Volun-
tary Cosmetic Registration Program which aims to enhance the safety labeling of cosmetic products).
1921 C.F.R. 740.10 (1975).
20Ian Indans, The use and interpretation of in vitro data in regulatory toxicology: cosmetics, toiletries and household products,
127 Toxicology Letters 177 (Feb. 28, 2002); Judith E. Foulke, Cosmetic Ingredients: Understanding the Puﬀery, FDA Con-
sumer, May 1992, available at, http://www.fda.gov/fdac/reprints/puﬀery.html (Cosmetic Ingredient Review (CIR) is sponsored
by the Cosmetic Toiletry and Fragrance Association).
21European Commission, The Rules Governing Cosmetic Products in the European Union (1999),
available at, http://www.leffingwell.com/cosmetics/vol 1en.pdf; Marleen Pauwels & Vera Rogiers,
Safety Evaluation of Cosmetics in the EU: Reality and challenges for the toxicologist, 151 Toxicology Letters 7 (June 15,
2004).
22Id.
23Pauwels & Rogiers, supra note 21.
511) Reproductive and developmental toxicity.24
The European cosmetic safety requirements coupled with the approaching Seventh Amendment deadline
has stimulated a frenzy of European eﬀorts toward validating non-animal toxicological safety tests.25 The
work researching and validating alternatives that has been done in Europe under the requirements of the
European Union “has had a spillover eﬀect in the United States, where the issue [of ﬁnding alternatives to
animal testing] had otherwise lost some momentum in the 1990’s.”26 In fact, once an alternative method is
validated by ECVAM, it is typically put under an expedited review process by ICCVAM for validation in
the United States.27
The Process of Developing and Validating Alternative Toxicological Tests
Toxicological tests evaluate the eﬀects of chemical exposure on the health and morality of living creatures.28
Toxicity tests have traditionally been performed on animals despite admission that “Most animal tests over or
underestimate toxicity, or simply don’t mirror toxicity in humans very well.”29 Moreover, non-animal toxicity
tests must go through a rigorous validation process to prove that the test accurately predicts a speciﬁc eﬀect
in humans, even though the animal tests traditionally relied upon never underwent any scientiﬁc validation
process.30 The validation process
24New Methods Replace Animal Testing for Cosmetics, supra note 13.
25See Abbott, supra note 8, at 145-46.
26An Overview of Animal Testing Issues, supra note 1, at 18.
27Megan Erin Gallagher, Toxicity Testing Requirements, Methods and Proposed Alternatives, 26 Environs Envtl. L. & Pol’y
J. 253, 265 (2003).
28Id. at 253; Stacy E. Gillespie, Animal Testing A Cover-Girl Face Does Not Have to Begin with Animal Cruelty: Chapter 476 Gives Legal Force to Alternative Testing
Methods, 32 McGeorge L. Rev. 461, 463 (2001).
29Abbott, supra note 8, at 144-45; Accord Gallagher, supra note 27, at 254 (stating “Many animal tests have led to results
that are inaccurate in humans, and some have led to death and deformity caused by products that initially appeared to be
nontoxic to nonhumans.”); Gillespie, supra note 28, at 464-65.
30Abbott, supra note 8, at 145; An Overview of Animal Testing Issues, supra note 1, at 8.
6typically requires testing a new protocol in three or four diﬀerent external laboratories.
The test chemicals are analysed by personnel who do not know the compounds’ identities.
If a test proves reproducible, it is sent for peer review by ECVAM’s Scientiﬁc Advisory
Committee, whose members include scientists, representatives from all member states of
the European Union and relevant industrial and animal-welfare groups. Once approved by
the committee, the test is adopted by the European Chemical Bureau, also located in Ispra,
and then sent to the [Organization of Economic Co-operation and Development] OECD for
the all-important global validation.31
Researchers developing alternative test methods follow the Three Rs: reduction, reﬁnement, and replacement,
advocated by the British researchers Russell and Burch in their 1959 book The Principles of Humane Experimental Technique.32
Reduction occurs when new methods allow the use of fewer animals. Reﬁnement occurs when a method is
changed to minimize the animals’ pain and distress. Replacement occurs when a new method or new meth-
ods are able to take the place of an animal test entirely.33 Replacement is the ultimate goal of animal rights
advocates;34 and under the Seventh Amendment to the Cosmetics Directive, replacement tests are the only
acceptable alternatives.35 Therefore, I will focus my attention on the progress being made in validating
replacement alternatives to animal testing for cosmetics.
The Cosmetic Industry Has Already Done Some of the Leg-Work
Animal rights conscious cosmetic companies36 have been developing and implementing alternative safety
assessment methods for years (in addition to giving grants to outside researchers).37 These companies have
been conducting “in house validation” studies by comparing the results obtained through alternative methods
32History of Alternatives, Altweb, available at, http://altweb.jhsph.edu/history.htm.
33See Id.
34Karen Lee Stevens, Animal Testing Alternatives, All For Animals (2000), available at,
http://www.allforanimals.com/alternatives1.htm.
35Rosholt, supra note 6, at 446.
36Cosmetic companies are also economically motivated to develop and implement non-animal tests because the cost of animal
upkeep in laboratories can be expensive. See Fleetwood, supra note 5.
37Tony Vinas, P&G Seeks Alternatives to Animal Tests, Industry Week, July 2004; Jacques LeClaire & Odile de Silva,
Industry Experience with Alternative Methods, 102-103 Toxicology Letters 575 (Dec. 28, 1998) (L’OREAL has been using
alternative methods for almost 30 years).
7to historical data from in vivo animal tests.38
When ECVAM began conducting formal validation studies of alternative methods under the instruction of the
European Union, the cosmetic companies eagerly submitted their testing techniques for consideration: “The
cosmetics industry is committed to develop and help validate alternative safety tests of particular relevance
to cosmetics.”39 For example, when ECVAM scheduled a prevalidation study of alternative methods to
test skin irritation, L’Oreal proposed a prediction model based on the assessment of cutaneous irritancy of
chemicals on EPISKIN, a reconstructed epidermis model.40 As a result of this coordinated eﬀort, ECVAM
validated EPISKIN as an alternative method for testing skin corrosion.41 The cosmetic industry also has wide
experience in the ﬁeld of percutaneous absorption which it shared and discussed with regulatory bodies.42
Validated Alternatives That Replace Animal Tests for Cosmetics
As of November 2005 a total of seventeen alternative tests had been validated by ECVAM.43 However, only
eleven use in vitro44 methods and thus replace in vivo tests; the remaining six validated alternatives reﬁne
in vivo tests to reduce the number of animals used, but do not replace animals.45 An additional forty
alternative tests are currently going through the peer review stage of validation with even more alternative
38LeClaire & de Silva, supra note 37.
39Id.; Accord New Methods Replace Animal Testing for Cosmetics, supra note 13 (quoting Dr. Thomas Hartung of ECVAM
as saying “Many [cosmetic companies] are interested in participating [in the validation of alternative methods] at an early stage
because they will be able to use these innovative methodologies for predictive testing, agent discovery and agent proﬁling even
before the tests become mandatory. They promise higher throughput, lower costs and better public acceptance – and thus oﬀer
real market advantages.”).
40Id.
41Michael K. Robinson, John P. McFadden & David A. Basketter, Validity and Ethics of the Human 4-h Patch Test to Assess Acute Skin Irritation Potential,
45 Contact Dermatitis 1 (July 2001), citing J.H. Fentem et al., The ECVAM International Validation Study on In Vitro Tests for Skin Corrosivity. 2. Results and Evaluation by the Management Team,
12 Toxicology In Vitro 483 (1998).
42LeClaire & de Silva, supra note 37.
43Abbott, supra note 8, at 145 (it is not clear that all seventeen validated tests can be used as alternatives for the cosmetic
industry rather than alternatives for non-cosmetic products).
44“In vitro testing is deﬁned as ‘a biological process made to occur in a laboratory vessel or other controlled experimental
setting rather than within a living organism....”’ Gillespie, supra note 28, at 467, quoting Random House Unabridged Dictionary
1004 (2d. ed, 1993).
45Gillespie, supra note 28, at 467.
8testing methods to come.46 As these statistics reveal, in vitro methods have been the most successful source
of replacement tests validated to date. In this section, I will discuss the current validation status and future
prospects in each of the eleven toxicological testing areas outlined above. I will describe the alternative tests
in the areas of skin corrosion and irritancy, eye irritation, skin absorption and penetration, and UV-induced
toxicity in greater detail because these are the areas where alternatives are more fully developed and the
most progress has been made toward total animal replacement.
Acute Toxicity
The traditional method of testing acute toxicity is the Lethal Dose 50 test (LD50).47 The LD50 is used
to ﬁnd the lethal dose for 50% of the sample of animals tested.48 During the test period the animal is
forced to inhale, ingest or is exposed in some other way (such as intravenous or dermal exposure) to the test
substance.49 Despite long-term research eﬀorts, no replacement alternatives have been validated by ECVAM
or ICCVAM.50 The LD50 has been replaced by less traumatic, but still fatal alternatives.51
The Multicenter Evaluation of In Vitro Cytotoxicity (MEIC) has been working on in vitro alternatives to
acute toxicity tests since 1989.52 MEIC has found that in vitro human cell lines can predict acute toxicity in
humans for most chemicals tested.53 MEIC narrowed their battery of tests down to the most predictive four
46Id. (it is not clear how many of these alternatives are replacement alternatives and it is unclear how many of them can be
used as alternatives for the cosmetic industry).
47John McArdle, The Search for Alternatives in Cosmetic Testing, American Anti-Vivisection Society,
available at, http://www.sniksnak.com/aavs4.html; Joanne Zurlo, Deborah Rudacille & Alan M. Goldberg,
Animal and Alternatives in Testing: History, Science, Ethics, Johns Hopkins University Center for Alternatives to Ani-
mal Testing (2002), available at, http://caat.jhsph.edu/pubs/animal alts/animal alts.htm.
48Zurlo, Rudacille & Goldberg, supra note 47; Spira, supra note 2.
49Gallagher, supra note 27, at 258; An Overview of Animal Testing Issues, supra note 1, at 15.
50In Vitro Methods for Assessing Acute Systemic Toxicity, ICCVAM, available at, http://iccvam.niehs.nih.gov/methods/invitro.htm.
51McArdle, supra note 47.
52Id. (MEIC created 61 in vitro assays for assessing acute toxicity); See also Laura Gribaldo et al., Acute Toxicity,
in Report for Establishing the Timetable for Phasing Out Animal Testing for the Purpose of the Cosmetics Directive,
available at, http://pharmacos.eudra.org/F3/cosmetic/doc/AnTest/(5)%20Chapter%203/1%20Acute%20Tox.pdf
(describing the numerous in vitro methods for testing acute toxicity); The MEIC Program, available at,
http://www.cctoxconsulting.a.se/meic.htm.
53McArdle, supra note 47.
9in vitro tests and they recommend using the four tests in combination to test products for acute toxicity.54
Many of MEIC’s methods are considered prevalidated even though it is uncertain how much longer it will
take for ECVAM and ICCVAM to formally validate these methods.55
In addition to MEIC’s research, project A-cute-tox is currently working to develop a simple and robust in
vitro testing strategy for predicting acute oral toxicity in humans.56 If this project is successful, it could
totally replace animal acute toxicity tests:
the time estimated to achieve complete animal replacement for acute toxicity is strongly
dependent on the outcome of this project [A-cute-tox], which represents the ﬁrst attempt to
create an integrated strategy to be validated with the purpose to predict human systemic
toxicity, and it cannot be less than 10 years.57
Currently, ECVAM and ICCVAM’s supporting center NICEATM are jointly working on the In Vitro Cyto-
toxicity Validation Study seeking to validate two in vitro basal cytotoxicity assays proposed as alternatives
to in vivo acute toxicity alternatives.58 The two methods under evaluation are the neutral red uptake assay
using mouse cell lines and the neutral red uptake assay using human cells.59 However, these two alternatives
will only be used to predict starting doses for in vivo acute toxicity tests; thus, they are not total replacement
alternatives.60
Skin Irritation and Corrosion
The traditional method of testing skin irritation and corrosion is the Draize rabbit skin irritation test.61 The
54Id.
55Gribaldo et al., supra note 52.
56Id.; Sandra Coecke et al., The value of alternative testing for neurotoxicity in the context of regulatory needs, Envi-
ronmental Toxicology & Pharmacology (2005), available at, http://caat.jhsph.edu/dnt/background/Coecke%20et%20al.pdf;
Simon Pitman, EU pushes for alternatives to animal testing, Decision Media News, Aug. 24, 2005, available at,
http://www.cosmeticsdesign-europe.com/news/ng.asp?n=62071-ecvam-animal-testing.
58In Vitro Methods for Assessing Acute Systemic Toxicity, supra note 50.
59Id.
60Id.
61Robinson, McFadden & Basketter, supra note 41.
10Draize skin irritancy test is performed by shaving the rabbit and then abrading the skin by pressing adhesive
tape against the skin and quickly stripping it oﬀ until several layers of skin are removed.62 Although the
Draize test has been criticized for not being able to reliably predict human skin reactions, it has been used
for over ﬁfty years.63
The Transcutaneous Electrical Resistance (TER) Assay, an in vitro test for assessing the corrosivity of
chemicals, was validated by ECVAM in March 1998 (and by ICCVAM in May 2004 after expedited review).64
The TER Assay evaluates corrosivity based on the observation that corrosive substances reduce the electrical
resistance of the skin.65 The TER Assay only reveals whether the substance is corrosive or not; it does
not discriminate between levels of corrosiveness.66 Although the TER Assay is considered a replacement
alternative, it uses rat skin cells and does involve killing animals to obtain fresh skin cells.67
EpiDerm and EPISKIN68 are three dimensional in vitro tissue cultures of human skin used to test chemical
corrosivity.69 They were validated by ECVAM in March 1998 (and by ICCVAM in May 2004 after expedited
review).70 To administer the test, a chemical is applied to the tissue cultures and cell death is recorded
62Animals in Product Testing: Animal Tests, National Anti-Vivisection Society, available at,
http://www.navs.org/site/PageServer?pagename=ain pt animal tests; Gallagher, supra note 27, at 258.
63Animals in Product Testing: Animal Tests, supra note 62; Robinson, McFadden & Basketter, supra note 41.
64An Overview of Animal Testing Issues, supra note 1, at 20; Dermal Corrosivity Assays: EPISKIN, EpiDerm and the Rat Skin Transcutaneous Electrical Resistance (TER) Assay,
ICCVAM, available at http://iccvam.niehs.nih.gov/methods/epiderm.htm.
65An Overview of Animal Testing Issues, supra note 1, at 20.
66Indans, supra note 20.
67An Overview of Animal Testing Issues, supra note 1, at 20 (noting that although rats must be killed for the TER Assay it
reduces the number of animals needed per chemical from 3 to 1 and it is a reﬁnes traditional corrosiveness tests because the
animals are not exposed to any pain or distress from the corrosivity test).
68Corrositex is another artiﬁcial skin in vitro test validated by ICCVAM and ECVAM to test skin corrosivity of acids, bases
and acid derivatives, but since Corrositex is not as sensitive as EPISKIN or EpiDerm, it does not completely replace animal
skin corrosivity tests. Instead, Corrositex is used to weed out highly corrosive substances, but if a substance passes Corrositex,
it is still tested on an animal. Gallagher, supra note 27, at 269-70; Indans, supra note 20.
69Gallagher, supra note 27, at 269.
70An Overview of Animal Testing Issues, supra note 1, at 21; Dermal Corrosivity Assays: EPISKIN, EpiDerm and the Rat Skin Transcutaneous Electrical Resistance (TER) Assay,
supra note 42.
11throughout a deﬁned exposure period.71 The validation studies revealed that EPISKIN is useful for testing
cosmetics, sunscreens and other topical products.72 EpiDerm and EPISKIN are superior to the TER Assay
because they can discriminate between level of corrosiveness and because no animal must be killed to perform
the test.73
Currently, no alternative tests are validated for testing skin irritation.74 However, EpiDerm is undergoing
validation studies and is expected be approved as an alternative test for skin irritation in the near future.75
Others believe that skin irritancy testing is safe and ethical to conduct on humans once a product has
been determined non-corrosive using in vitro methods.76 For example, the 4-h human patch test has been
shown to be low in risk; subjects experience mild to moderate reactions at the site of exposure and recover
quickly.77 To administer the test, a small amount of the test substance is applied to a patch placed against to
upper outer arm of the human subject.78 After the exposure period, the patch is removed and the irritation
response is measured.79
Eye Irritation
The traditional eye irritation test, called the Draize eye irritation test was developed by the FDA after a
series of reports that women were suﬀering permanent eye injuries from cosmetic products.80 One woman
even went blind after eyelash dye destroyed her eyeballs.81 The Draize eye irritation test is performed by
71Gallagher, supra note 27, at 269.
72An Overview of Animal Testing Issues, supra note 1, at 21.
73Indans, supra note 20 (Human skin equivalence models discriminate between R34 (causes burns) and R35 (causes severe
burns))
74Id. (noting that although no skin irritation tests have been validated, if a product or ingredient fails the in
vitro corrosivity tests it is not testing on animals); Thomas Welss, David A. Basketter & Klaus R. Schroder,
In vitro skin irritation: facts and future. State of the art review of mechanisms and models, 18 Toxicology In Vitro 231 (2004).
75Fleetwood, supra note 5; See also New Methods Replace Animal Testing for Cosmetics, supra note 13.
76Robinson, McFadden & Basketter, supra note 41; McArdle, supra note 47.
77Robinson, McFadden & Basketter, supra note 41.
78Id.
79Id.
80Abbott, supra note 8, at 144; Gillespie, supra note 28, at 464.
81Abbott, supra note 8, at 144, Rosholt, supra note 6, at 421.
12placing the test substance in one eye of a rabbit, without local anesthetic, while the other eye is used as
a control.82 Clips are placed on the eyelids to hold the eyes open and to keep the animals from blinking
the product away and the animals are placed in restraining stocks to prevent them from moving during the
test period.83 Eye irritation levels are then observed over several days with maximum irritation being total
destruction of the eye.84
The Draize eye irritation test was the test that prompted the animal rights activists to protest Revlon and
other cosmetic companies dressed as bunnies.85 Thus, when CAAT was created, their primary mission was
to discover an alternative to this test.86 However, thus far neither ECVAM nor ICCVAM have validated a
non-animal eye irritancy test.87 Reductions and reﬁnements of in vivo tests have been implemented, but
these changes have not eliminated the need to use live animals.88 Despite the slow progress, many eye
irritancy replacement alternatives are near ﬁnal validation by ECVAM and ICCVAM and alternatives are
already being used in the industry.89 It is unlikely that a single in vitro test will be able to replace the Draize
eye test, but a battery of in vitro alternatives used together can probably replace in vivo eye irritancy tests
in the near future.90
Several in vitro techniques use isolated eyes, corneas and lenses freshly obtained from slaughterhouses or
82An Overview of Animal Testing Issues, supra note 1, at 11.
83Animals in Product Testing: Animal Tests, supra note 62.
84An Overview of Animal Testing Issues, supra note 1, at 11.
85Id.; Spira, supra note 2.
86An Overview of Animal Testing Issues, supra note 1, at 12.
87McArdle, supra note 47; Indans, supra note 20.
88Eskes, et al., Eye Irritation, 33 Alternatives to Laboratory Animals 47 (2005) (for example, the low volume eye test (LVET)
uses less test substance in the Draize eye test to reduce the pain endured by the rabbit, but this reﬁnement method has not yet
been validated).
89In Vitro Test Methods for Detecting Ocular Corrosives and Severe Irritants, ICCVAM, November 2005, available at,
http://iccvam.niehs.nih.gov/methods/eyeirrit.htm; New Methods Replace Animal Testing for Cosmetics, supra note 13 (stat-
ing that there are 14 in vitro alternatives being used in the industry or being developed); Fleetwood, supra note 5.
90Eskes, et al., supra note 88, at 68.
13from animals used in other toxicological studies.91 The test substance is administered to the eye and the
eye is observed for toxic reaction at any level.92 For example, the Bovine Corneal Opacity and Permeability
(BCOP) Assay is used by several cosmetic companies and has been shown well suited for identifying sub-
stances which are moderately and severely irritating to the eye.93 But, the BCOP assay has not proven as
sensitive in distinguishing among mild irritants; and therefore, it is suggested that the BCOP assay be used
in combination with other tests.94 The Isolated Rabbit Eye (IRE) test and the Chicken Enucleated Eye Test
(CEET) have both only proven useful for identifying severely irritating substances.95 Although the isolated
eye methods are considered replacement alternatives, animal rights activists have two problems with them:
(1) live animals are still needed to test for mild irritation once a substance passes these tests and (2) animals
must be killed to perform these tests.96
Another method for testing eye irritation is the Hen’s Egg Test on the Chorio-allantoic Membrane (HET-
CAM) Assay which exposes the chorio-allantoic membrane of fertilized chicken eggs to test chemicals.97
The test is performed before the fertilized egg has developed nerve tissue and therefore is believed to cause
no pain.98 To perform the test, the test substance is applied to the membrane and then the membrane is
observed over a 5-minute period for hemorrhage, lysis and coagulation.99 This test has been found useful
for identifying mild and non-irritating substances and because of its limited range it is recommended for use
in conjunction with other eye irritancy tests.100 The Chorio-allantoic Membrane Vascular Assay (CAMVA)
and the Chorio-allantoic Membrane: Trypan Blue Staining (CAM-TB) Test are related methods which can
91Id. at 48 (bovine, porcine, chicken or rabbit organs are all used).
92Id. at 49.
93Id. at 49-50; LeClaire & de Silva, supra note 37.
94Id. at 50.
95Id. at 51-52.
96An Overview of Animal Testing Issues, supra note 1, at 13-14.
97Id. at 13; Eskes, et al., supra note 88, at 53; McArdle, supra note 47.
98Eskes, et al., supra note 88, at 53.
99Id.
100Id. at 54.
14also be used in combination with other eye irritancy tests.101
Reconstructed human tissue models are in vitro methods that oﬀer completely animal free replacements
for testing eye irritancy.102 For example, EpiOcular is a multi-layered culture of human cells that mimics
the structure of the human cornea.103 EpiOcular is most often used to identify mild or moderate irritants,
but can also identify potentially severe irritants (EpiOcular cannot diﬀerentiate between degrees of severe
irritancy).104 EpiOcular is near ﬁnal validation105 and is already being used by the cosmetics, personal
care, household and industrial chemical industries.106 Other human tissue models in the process of being
developed and tested are the SkinEthic In Vitro Reconstituted Human Corneal Epithelium (HCE) Model
and the Gillette HCE-T Tissue Construct Model.107
Cell based cytotoxicity alternatives measure cell viability to predict eye irritancy.108 For example, the Neu-
tral Red Uptake (NRU) Assay measures the ability of a substance to inhibit the uptake of a dye marker of
cell viability.109 After exposing the cells to the test substance, the dye is applied and researchers observe
how much dye the cells uptake; uptake is decreased if the cells have been altered by the test substance.110
The NRU is useful for identifying moderate to severely irritating substances and can be used in combination
with in vitro methods able to test mild irritancy such as the HET-CAM.111 The related Neutral Red Release
(NRR) Assay is able to diﬀerentiate degrees of mildness in the mild to very mild range following brief, high
concentration contact with a test substance.112
101Id. at 54-55.
102McArdle, supra note 47.
103Id.
104Eskes, et al., supra note 88, at 56.
105Fleetwood, supra note 5.
106Eskes, et al., supra note 88, at 56.
107Id. at 57.
108Id. at 58; An Overview of Animal Testing Issues, supra note 1, at 13.
109Eskes, et al., supra note 88, at 58.
110Id.
111Id. at 58-59.
112Id. at 59- 60 (also discussing the Red Blood Cell (RBC) Haemolysis Test).
15Cell function assays measure the eﬀects of a test substance by observing changes in cell function.113 The
Fluorescein Leakage (FL) Test assesses the eﬀects of a test substance on an in vitro cell model of the corneal
epithelium.114 The cells are exposed to the test substance and then tested for changes in permeability.115
The FL test has shown promise when used in combination with other non-animal eye irritation tests.116
The Silicon Microphysiometer (SM) Assay measures changes induced by chemical substances on metabolic
activity of cells.117 The cells are grown in a pH sensitive chamber which causes the cells to release acidic
metabolic products establishing a baseline metabolic rate.118 The cells are then exposed to the test substance
and changes in the metabolic rate are measured.119 The SM assay has been found reliable for classifying
certain types of substances as innocuous-mild, mild-moderate or moderate-severe.120
The IRRITECTION assay is the updated protocol of the EYTEX system.121 This biochemical assay is
based on the premise that eye irritation and corneal opacity from chemicals is the result of perturbation or
denaturation of corneal proteins.122 To perform the test, changes to a protein solution are observed follow-
ing exposure to the test substance.123 However, IRRITECTION needs to undergo further research before it
could be considered for validation.124
Finally, the Pollen Tube Growth (PTG) Assay exposes pollen from tobacco plants to a test substance for 18
hours.125 The mass of pollen tubes produced during this period is photometrically determined to ascertain
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16shown to correlate well with the Draize eye irritation test for substances with very low to moderate irritation
potentials.127 However, more validation studies need to be performed on this method.128
Skin Sensitization
Skin sensitization tests are used to identify potential allergic reactions to products; a serious safety consider-
ation for cosmetic manufacturers.129 The traditional method of testing skin sensitization involved exposing
guinea pigs’ skin to the substance, intentionally increasing the animals’ sensitivity and observing the animals’
reaction.130 Currently, the only validated alternative is the Local Lymph Node Assay (LLNA), which also
uses animals and requires those animals to be killed.131
Despite the fact that the LLNA is the only validated alternative for testing skin sensitization, in vitro re-
constructed human skin models are being studied as potential replacement alternatives.132 Research teams
in Europe have made progress with a human reconstructed epidermis model containing Langerhans cells
(immunological cells in the skin).133 Further research and reﬁnement of the in vitro skin sensitization tests
are needed and it is likely that more than one alternative sensitization test will be needed to replace animal
tests considering the complexity of in vivo skin sensitization reactions.134
In addition to in vitro research, in silico systems are being developed to test skin sensitization and validation
is expected within ﬁve to six years.135 In silico systems use computer models or computer simulations to
127Id.
128Id. at 65.
129McArdle, supra note 47.
130Id.
131Id. (the LLNA is both a reduction and a reﬁnement alternative test, but not a replacement);
Murine Local Lymph Node Assay (LLNA), ICCVAM, available at, http://iccvam.niehs.nih.gov/methods/llna.htm;
An Overview of Animal Testing Issues, supra note 1, at 20.
132McArdle, supra note 47.
133R. Schmidt, C. Duval & M. Regnier, Reconstructed Human Skin: Alternative Models for the Safety and Eﬃcacy Assessment of Dermato-Cosmetological
Products, 27 Alternatives to Laboratory Animals 81 (1999) (abstract), available at,
http://www.invitroderm.com/abstracts/schmidt.html; LeClaire & de Silva, supra note 37.
134New Methods Replace Animal Testing for Cosmetics, supra note 13.
135Id.
17replace physical experiments.136 In silico systems may never fully replace physical experiments, but new
substances can be pre-screened using computer models and if the computer determines the substance is likely
to be dangerous, then the substance can be rejected without further testing.137
Skin Absorption and Penetration
The traditional animal test for assessing skin absorption and penetration is performed by applying the test
substance to the surface of a rat’s skin for a speciﬁed period of time.138 The animal is then terminated and
the amount of dose associated with the skin, carcass and in excreta is calculated.139
In vitro alternatives using reconstructed skin models (similar to EpiDerm and EPISKIN) can also be used
to test skin absorption and penetration.140 Although these alternatives have not undergone validation
by ECVAM or ICCVAM, OECD Guidelines already exist for using alternative in vitro skin absorption
and penetration tests; based on OECD acceptance these methods can be assumed to be internationally
accepted.141 To perform the in vitro skin absorption and penetration test, the test substance is applied
to the reconstructed skin for a speciﬁed period of time.142 The receptor ﬂuid, the ﬂuid under the surface
of the reconstructed skin, is then sampled to determine the mass (and possibly the rate) of absorption.143
These in vitro alternatives are limited by the fact the reconstructed skin models cannot fully simulate the
eﬀects of peripheral blood ﬂow, but “skin absorption is primarily a passive process and studies undertaken
using appropriate in vitro experimental conditions have produced data for a wide range of chemicals that
136Alternative Testing Methods: European research to replace and reduce animal tests, June 23, 2004, available at,
http://europa.eu.int/comm/research/press/2004/pr2306en.cfm.
137Grant Buckler, A Diﬀerent Kind of Laboratory Mouse, Nov. 20, 2004, available at,
http://www.digitaljournal.com/news/?articleID=4045.
138Guidance Document for the Conduct of Skin Absorption Studies: OECD Series on Testing and Assessment, March 2004,
at 13, available at, http://appli1.oecd.org/olis/2004doc.nsf/43bb6130e5e86e5fc12569fa005d004c/4ba210c177892390c1256e4e00379b6a/$FILE/JT00159305.PDF.
139Id.
140Id.
141Timetables for the phasing-out of animal testing in the framework of the 7th Amendment to the Cosmetics Directive (Council Directive 76/768/EEC),
Commission of the European Communities (2004), at FN 6, available at, http://pharmacos.eudra.org/F3/cosmetic/doc/AnTest/sec 2004 1210 en.pdf.
142Id.
143Id.
18demonstrate the usefulness of this method.”144
Subacute and Subchronic Toxicity
For cosmetic products oral, dermal and inhalation subacute (28 days) and subchronic (90 days) repeated
dose studies are important safety tests.145 The currently accepted testing methods use rodents and there are
no accepted or validated alternative methods for replacing in vivo tests.146 Finding replacement alternatives
represents an enormous scientiﬁc and technical challenge because of the complexity of the information col-
lected from in vivo tests: “the eventual replacement of in vivo repeat-dose toxicity tests must involve some
integration of in vitro data on target organ toxicity with in vitrolin silico data...”147
Preliminary research has been done to develop in vitro models to test subacute and subchronic toxicity
in the liver, kidneys, central nervous system, lungs and haematopoietic system.148 And, the Predictomics
project is currently working to develop in vitro systems capable of predicting long-term renal and hepatic
toxicities in humans.149 However, these alternatives are at the early stages of research and development
and no alternative methods are yet available for actual implementation.150 Moreover, “none of the in vitro
models we currently have is ideal for any of the target organs and therefore some eﬀorts should be put to
optimise the models available and to look for good in vitro models in those cases w[h]ere fewer models are
available (e.g. in vitro models to study lung toxicity).”151
Genotoxicity and Mutagenicity
144Id. at 12.
145Pilar Prieto et al., 3.6 Subacute and subchronic toxicity, in Report for Establishing the Timetable for Phasing Out Animal Testing for the Purpose of the Cosmetics Directive





149Coecke et al., supra note 56.
150Prieto et al., supra note 145 at 11.
151Id. at 15.
19Mutagenicity refers to a substance’s ability to induce permanent mutations in the structure of genetic
material.152 Genotoxicity refers to a substance’s ability to interact with DNA.153 Researchers are looking
for three diﬀerent things when they test a substance for genotoxicity and mutagenicity: gene mutations,
clastogenicity and aneuploidy.154 Currently, there is no single validated in vitro test that can provide
information on all three endpoints; therefore, a battery of tests is needed to fully assess the genotoxic and
mutagenic proﬁle of a test substance.155 Many of the in vitro methods for assessing mutagenicity and
genotoxicity are accepted by regulatory authorities worldwide and commonly used by the cosmetic industry
(in a standard battery of in vitro tests), but in vivo tests are still used as a back-up when needed.156
The in vitro tests for mutagenicity and genotoxicity accepted by regulatory authorities and recommended for
use as part of an in vitro battery of tests include: the Mammalian chromosome aberration test, the Bacterial
reverse mutation test, the Mammalian cell gene mutation test, and the unscheduled DNA synthesis (UDS)
in mammalian cells.157 The In vitro mammalian micronucleus assay is also recommended for use as part of
an in vitro battery of tests, but it has not yet been formally accepted by regulatory authorities.158 The In
vitro Comet assay is used by the cosmetic industry to test for DNA damage, but it has not been validated
and is not currently undergoing any validation studies.159
The Saccaromyces Cerevisiae gene mutation assay and the Saccaromyces Cerevisiae mitotic recombination
assay are accepted by regulatory authorities, but are no longer recommended for use in the standard battery
152Maurier et al., Genotoxicity/mutagenicity, in Establishment of Timetables for the Phasing out of Animal Experiments for Cosmetics,









20of tests.160 The Sister chromatid exchange (SCE) assay in mammalian cells is another in vitro mutagenicity
test that is rarely used today, but has been accepted by regulatory authorities.161
Three dimensional reconstructed skin models by SkinEthic and EpiDerm are used by the cosmetic industry
to test for photomutagenicity, but they have not yet been validated for this purpose.162 Much more research
is needed before any in vitro skin models will be validated to test for photomutagenicity.163
Despite the numerous in vitro methods for testing mutagenicity and genotoxicity, mentioned above, in vitro
tests are limited by the fact that they cannot show toxicokinetic or metabolic interactions.164 Considering
the slow progress in developing alternatives in toxicokinetics and metabolism (see below), it is unlikely that
in vivo tests for genotoxicity and mutagenicity can be fully replaced in the near future.165 Nevertheless, the
current battery of in vitro tests is being used to dramatically reduce the number of in vivo tests needed.166
UV-Induced Toxicity
The 3T3 Neutral Red Uptake Phototoxicity Test (3T3 NRU PT) was the ﬁrst replacement test validated
in Europe.167 To perform the test, the test substance is added to an in vitro culture of skin cells which is




163See Id. at 16-17.
164See Id. at 22.
165Id. (estimating that full replacement will not be feasible within the next 12 years).
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167Abbott, supra note 8, at 146 (in overleaf “The Validation Game”); An Overview of Animal Testing Issues, supra note 1, at
21; LeClaire & de Silva, supra note 37, at 190.
168Abbott, supra note 8, at 146 (in overleaf “The Validation Game”); McArdle, supra note 47; See also Manfred Liebsch
et al., UV-induced eﬀect, in Establishment of Timetables for the Phasing Out of Animal Experiments for Cosmetics (2004),
available at, http://pharmacos.eudra.org/F3/cosmetic/doc/AnTest/(5)%20Chapter%203/8%20UV%20induced%20eﬀects.pdf
(for a more technical description of the method).
21and after irradiation is monitored to assess phototoxicity.169 ICCVAM has also determined that the 3T3
phototoxicity test is predictive of phototoxicity in humans and animals.170 This method has been oﬃcially
accepted for all types of products, not just cosmetics.171
The Red Blood Cell Phototoxicity Test (RBC PT) is an in vitro test that can identify photosensitizers and
study the phototoxic mechanisms at the cellular level.172 This test provides information about photodynamic
reactions which is useful in evaluating overall safety.173 A testing strategy can start with the 3T3 NRU PT
test and then use the RBC PT test to provide the photodynamic information not provided by the 3T3 NRU
PT test.174
EpiDerm, the reconstructed human skin model, is also being studied for its potential ability to test photo-
toxicity.175 EpiDerm may be suitable for testing substances that cannot be tested using the 3T3 NRU PT
Test.176 It can also be used to further investigate substances which resulted in potentially false positives
under the 3T3 NRU PT Test.177 In vitro reconstructed skin models are already used by the industry, in
combination with the other tests mentioned, to evaluate sunscreen eﬃcacy and safety.178
Toxicokinetics and Metabolism
Toxicokinetics and metabolism studies show researchers how a test substance is absorbed into an organ-
ism, distributed throughout the organism, metabolized and excreted.179 Currently, research is being done
169Id.
170In Vitro 3T3 NRU Phototoxicity, ICCVAM, available at, http://iccvam.niehs.nih.gov/methods/3t3 nru.htm.
171McArdle, supra note 47.
172Liebsch et al., supra note 168.
173Id.
174Id.
175Id.; McArdle, supra note 47; Fleetwood, supra note 5.
176McArdle, supra note 47.
177Liebsch et al., supra note 168.
178LeClaire & de Silva, supra note 37.
179New Methods Replace Animal Testing for Cosmetics, supra note 13.
22to develop both in vitro and in silico methods for assessing toxicokinetics and metabolism.180 Although
signiﬁcant progress has been made, it is expected that complete replacement of in vivo tests will take over
ten years.181
Researchers are using a three tiered strategy to ensure that alternatives are developed to provide all nec-
essary information formerly obtained through animal tests.182 Tier 1 tests will be used to determine the
likelihood that an organism will have systemic exposure to a test substance via the dermal, oral or inhalation
routes.183 Tier 2 tests will be used to determine the distribution of the compound after systemic exposure
by developing ways to test plasma level, excretion, tissue distribution and metabolism.184 Lastly, Tier 3
tests will be used to determine the overall potency of a compound.185 Finding non-animal alternatives for
testing excretion is proving the most diﬃcult task, but it has been suggested that excretion testing is less
important for cosmetics than for chemicals and pharmaceuticals.186
Carcinogenicity
Carcinogenicity tests are rarely performed in the cosmetic industry, but non-animal alternatives to testing
carcinogenicity are nevertheless being researched for use in testing other substances.187 However, to date,
no alternative tests have been validated and companies testing for carcinogensis continue to use animals
(typically rodents).188 Moreover, because carcinogenesis is a complex, multi-step process, it is very diﬃcult
to build all the phases into a single in vitro model.189 Several in silico systems and models for predicting
180Id.; Sandra Coecke et al., Subgroup of Experts on Toxicokinetics and Metabolism in the context of the follow-up of the 7th
Amendment on the Cosmetics Directive, in Report for Establishing the Timetable for Phasing out Animal Testing for the Purpose of the Cosmetics Directive
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23carcinogenicity have been developed, but prediction success using these systems has been poor.190
Thus far, the two in vitro tests that have been proposed are the Cell transformation assay and the Gap junc-
tion intercellular communication (GJIC).191 Although these tests provide some information about carcino-
genic substances, they are insuﬃcient replacements for animal tests.192 Given the present state of developing
alternative carcinogenicity tests, “the experts were unable to suggest a deadline for full replacement.”193
Reproductive and Developmental Toxicity
Reproductive toxicity refers to the adverse eﬀects of a substance on any aspect of the reproductive cycle.194
Due to the complexity of human reproduction cycle, there are numerous toxicity endpoints that must be
tested, making it impossible for a single in vitro system to replace animal tests.195 However, the cycle can be
broken down into biological components that can be studied individually or in combination.196 Promising
in vitro models are already available for certain reproductive toxicity testing endpoints.197 Although in vivo
tests cannot be fully replaced until non-animal tests are developed for all aspects of reproductive toxicity
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24Research toward ﬁnding more non-animal alternatives for testing reproductive toxicity is being studied by
ReProTect, a European project aimed at developing non-animal alternative strategies for detecting repro-
ductive toxicants.199 ReProTect is exploring both in vitro and in silico methods.200 They have broken down
the entire reproductive cycle and are in the process of developing suitable tests.201
To date, ECVAM has validated three embryotoxicity tests: the whole embryo culture (WEC) test, the
micromass (MM) test, and the embryonic stem cell test (EST); and ICCVAM has validated the frog embryo
teratogenesis assay.202 However, these tests are limited in that they only cover single aspect of developmental
toxicity and many of them still rely on intact rodents as their source.203
Conclusion
In conclusion, progress toward developing and validating replacement alternatives to animal testing for
cosmetics is slow, but far from stagnant. The deadlines imposed by the Seventh Amendment to the Cosmetics
Directive in Europe have stimulated signiﬁcant advances in in vitro and in silico replacement alternatives.
Some alternatives have already been validated or internationally accepted and many more are in the process
of being validated. Moreover, new research projects are being funded to develop non-animal alternatives for
even the most complicated toxicity tests. Although the validation process through ECVAM and ICCVAM is
slow and conservative, the cosmetic industry is putting non-animal alternatives into practice as they develop,
sparing animals’ lives while not compromising the safety of cosmetic products.
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